Why Employers Must Understand CGT
Cell and gene therapies (CGTs) represent one of the most consequential shifts in modern medicine — and one of the most significant emerging challenges for employer-sponsored health plans. Unlike traditional drugs that manage symptoms chronically, CGTs aim to correct the underlying biological cause of a disease, often through a single administration. For employees and dependents living with rare genetic disorders, blood cancers, or inherited metabolic conditions, these therapies can be genuinely life-altering. Benefits leaders introduce an entirely new risk and coverage paradigm.
What Are These Therapies?
Cell therapy involves transferring living cells into a patient to treat a disease. Cells may come from the patient themselves (autologous) — as in chimeric antigen receptor T-cell (CAR-T) therapy, where a patient's immune cells are collected, genetically reprogrammed to attack cancer, and reinfused — or from a donor (allogeneic), as in hematopoietic stem cell transplantation (HSCT).
Gene therapy goes a step further: it uses genetic material to modify or replace the instructions inside a patient's cells. The U.S. Food and Drug Administration (FDA) defines human gene therapy as the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use.
Two delivery strategies underpin most approved therapies:
- In vivo gene therapy: The corrective genetic material is delivered directly into the patient's body — typically via a viral vector such as an adeno-associated virus (AAV) — targeting affected tissues without removing cells first. Examples include Luxturna (inherited retinal dystrophy) and Hemgenix (hemophilia B).
- Ex vivo gene therapy: Cells are extracted from the patient, genetically modified in a laboratory, and then reinfused. CAR-T therapies and the sickle cell disease (SCD) therapies Casgevy and Lyfgenia follow this approach.
A newer category, genome editing, uses tools such as CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR-Associated Protein 9) to make precise edits to a patient's existing DNA rather than adding new genetic sequences.
Why Employers Must Pay Attention Now
As of late 2024, the FDA had approved more than 40 cellular and gene therapy products, with the pipeline growing by roughly 6–7% annually according to the American Society of Gene & Cell Therapy (ASGCT). The FDA has projected that it could approve 30 to 50 CGTs per year by 2030. Prices range from roughly $300,000 to more than $4 million per treatment. For a self-insured employer, a single claim can exceed an entire year's pharmacy budget.
Employer Stakes
Approximately 80% of employers surveyed report concern that existing financing strategies will be insufficient to manage high-cost therapies. Yet the therapies also deliver potentially curative value: Hemgenix, priced at $3.5 million, is projected to save $5–$5.8 million per patient in long-term standard-of-care costs.
Key employer action areas include: population and pipeline risk assessment; coverage policy design; stop-loss insurance adequacy review; outcomes-based contract and alternative payment model exploration; Centers of Excellence (COE) credentialing for CGT administration; and clear employee communications.
The Centers for Medicare & Medicaid Services (CMS) launched its CGT Access Model in January 2025 — a multi-year outcomes-based pilot initially focused on sickle cell disease — signaling that government payers are also actively developing new payment frameworks that commercial employers can watch and potentially model.
Key Statistics
| >4200 |
Therapies in the global pipeline (2025) |
| 48 |
FDA-approved CGTs (2026) |
| $3.5M |
Hemgenix price (hemophilia B) |
| 80% |
Employers are concerned about CGT financing |
| 34 |
States in CMS CGT Access Model (early 2025) |
| 30-50 |
Projected annual FDA CGT approvals by 2030
|
Key Terminology Glossary
- Adeno-Associated Virus (AAV)
- A small, non-pathogenic virus commonly used as a vector to deliver therapeutic genes into cells in in vivo gene therapy. Its low immunogenicity and ability to target specific tissues make it the dominant delivery platform for approved in vivo gene therapies.
- Allogeneic Therapy
- A treatment using cells or genetic material from a donor rather than the patient. Allogeneic approaches can be manufactured at scale ("off-the-shelf"), reducing costs and wait times compared to autologous therapies.
- Autologous Therapy
- A treatment manufactured from the patient's own cells or tissue. The product is personalized but requires individual manufacturing, contributing to high costs and logistical complexity.
- CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy)
- An ex vivo cell therapy in which a patient's T cells are collected, genetically engineered to express a receptor targeting cancer cells, expanded in a laboratory, and reinfused. Approved for multiple blood cancers. Examples: Kymriah, Yescarta, Breyanzi, Carvykti.
- CBER (Center for Biologics Evaluation and Research)
- The FDA division responsible for regulating cellular therapy products, human gene therapy products, and related devices.
- CGT (Cell and Gene Therapy)
- An umbrella term encompassing cell therapies, in vivo gene therapies, and ex vivo gene-modified cell therapies.
- COE (Center of Excellence)
- A specialized healthcare facility with demonstrated clinical experience and quality outcomes for complex procedures, including CGT administration. Employers often contract with COEs to ensure appropriate patient selection and therapy delivery.
- CRISPR/Cas9
- Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR-Associated Protein 9. A gene editing technology that enables precise cuts and modifications to a cell's DNA. The basis for Casgevy, the first CRISPR-based therapy approved in the U.S., for sickle cell disease.
- Durability
- The length of time a gene or cell therapy remains effective after a single administration. A central evidence uncertainty because most approved therapies lack long-term follow-up data, creating risk for both patients and payers.
- Ex Vivo Gene Therapy
- A two-step approach: cells are removed from a patient, genetically modified outside the body, and then reinfused or transplanted. Most CAR-T and stem cell-based gene therapies use this approach.
- In Vivo Gene Therapy
- A gene therapy approach in which therapeutic genetic material is delivered directly into the patient's body, typically via a viral vector such as AAV, without removing cells first.
- ICER (Institute for Clinical and Economic Review)
- An independent nonprofit that assesses the clinical and economic value of health technologies. ICER's CGT evidence reports are frequently cited by payers in coverage and prior authorization decisions.
- OBA (Outcomes-Based Agreement)
- A contract between a payer and a manufacturer in which payment for a therapy is tied to real-world clinical outcomes. OBAs are a key strategy for managing the financial risk of high-cost, potentially durable therapies whose long-term effectiveness is uncertain.
- PBM (Pharmacy Benefit Manager)
- A third-party administrator of prescription drug programs for health plans. The role of PBMs in CGT management is evolving, as some employers explore direct contracting with specialty pharmacies rather than routing through traditional PBM channels.
- RMAT (Regenerative Medicine Advanced Therapy) Designation
- An FDA designation for regenerative medicine products — including cell and gene therapies — that treat serious conditions and show preliminary clinical evidence of potential to address unmet needs.
- Stop-Loss Insurance
- Insurance purchased by self-funded employers to protect against catastrophic claims. For CGTs, employers must carefully review stop-loss policy language, as some carriers exclude or cap coverage for gene therapy claims.
- Vector
- A delivery vehicle used to transport therapeutic genetic material into target cells. Viral vectors (AAV, lentivirus, adenovirus) are most common; non-viral delivery methods (lipid nanoparticles, plasmid DNA) are increasingly studied.
Resource Library
The primary landing page of the FDA's Center for Biologics Evaluation and Research (CBER) for all cellular and gene therapy oversight. Provides links to regulatory guidances, the approved product list, the Regenerative Medicine Advanced Therapy (RMAT) designation program, and the cellular, tissue, and gene therapy advisory committee.
A concise, authoritative FDA definition page explaining how gene therapies work — including mechanisms of gene replacement, inactivation, and introduction — and the categories of gene therapy products. Summarizes the regulatory pathway from investigational new drug application (IND) to biologics license application (BLA).
The official FDA registry of all licensed cellular and gene therapy products, maintained by the Office of Therapeutic Products (OTP). As of late 2024, the list includes more than 40 products spanning CAR-T (Chimeric Antigen Receptor T-cell) therapies, AAV (adeno-associated virus) gene therapies, CRISPR-based therapies, and hematopoietic stem cell products.
A comprehensive compendium of FDA guidance documents for manufacturers developing CGT products, covering manufacturing changes, comparability, and long-term follow-up requirements. Illuminates why CGT products are priced as they are — development costs exceed $5 billion on average.
The National Human Genome Research Institute's (NHGRI's) authoritative one-page definition of gene therapy, written for a broad audience. Covers gene addition, gene editing, and the spectrum of conditions treated. Useful as a plain-language primer for employee communications or benefits committee presentations.
A patient-facing overview from the National Library of Medicine (NLM) covering what genes are, what happens when genes change, and how gene therapy works, including ex vivo and in vivo approaches and genome editing (CRISPR/Cas9). Excellent resource to share with employees or HR generalists seeking accessible background.
The National Center for Advancing Translational Sciences (NCATS) toolkit entry defining cell therapy and its major subcategories: blood transfusions, hematopoietic stem cell transplantation (HSCT), and gene-modified cell therapy. Valuable for benefits managers distinguishing 'cell therapy' from 'gene therapy' in plan documents.
The National Heart, Lung, and Blood Institute (NHLBI) distinguishes gene transfer, genome editing, and cell-based gene therapy. Particularly relevant for benefits professionals managing claims for blood disorder therapies.
Compares gene addition, gene silencing, and gene correction — the three main strategies used in sickle cell disease (SCD) treatments. Directly actionable for benefits teams navigating coverage decisions for SCD gene therapies Casgevy and Lyfgenia.
Published quarterly by the American Society of Gene & Cell Therapy (ASGCT) in partnership with Citeline. As of Q4 2024, over 4,200 therapies were in development. Employers and benefits consultants can use this report to anticipate near-term coverage pressures and pipeline risk.
ASGCT's patient-facing educational hub providing accessible explanations of cell and gene therapy science, current clinical trials, and policies affecting patient access. Employer benefits teams can direct employees with relevant diagnoses to this portal as a trusted, non-commercial source.
ASGCT's central advocacy hub including formal policy statements on regulatory policy, payment policy, and federal research funding. The Payment Policy section addresses outcomes-based agreements (OBAs), coverage policies, and RMAT designation.
The Institute for Clinical and Economic Review's (ICER's) final evidence report assessing clinical effectiveness and cost-effectiveness of Casgevy and Lyfgenia for sickle cell disease (SCD). Estimated cost-effectiveness at prices between $1.35M and $2.05M. Includes evidence-based prior authorization criteria — the most directly actionable independent evidence review for employer SCD coverage policy.
ICER's landing page for all evidence reports including assessments of spinal muscular atrophy (SMA) gene therapy (Zolgensma), hemophilia B (Hemgenix), and other CGTs. Employers and pharmacy benefit managers (PBMs) can use ICER reports as independent benchmarks when evaluating manufacturer price justifications.
A peer-reviewed policy analysis examining payer coverage barriers — restrictive prior authorization, narrow interpretation of FDA-approved indications, administrative burdens, and portability problems. Key finding: rare diseases cost the U.S. economy $548 billion annually. Proposes outcomes-based agreements (OBAs), reinsurance, and federal policy reforms.
Projects per-member-per-month (PMPM) cost impact of sickle cell gene therapies on state Medicaid, finding average Year 1 impacts of $3.11 PMPM. Directly applicable to self-insured employer plan sponsors anticipating similar budget shocks.
Systematic review finding gene therapies would have lower overall costs and better outcomes than factor concentrate replacement if treatment effects are durable for at least 10 years. Supports outcomes-based agreements (OBAs) similar to the CMS (Centers for Medicare & Medicaid Services) model.
Evaluates outcomes-based agreement (OBA) designs for Casgevy and Lyfgenia from the perspective of Colorado Medicaid using real-world data. Examines the CMMI (Centers for Medicare & Medicaid Services Innovation Center) CGT Access Model as a template for self-insured employers.
Official page for the CMS CGT Access Model — a multi-year voluntary model in which the Centers for Medicare & Medicaid Services (CMS) negotiates outcomes-based agreements (OBAs) on behalf of participating state Medicaid programs. As of early 2025, 34 states and 2 manufacturers participate. Sets precedent for commercial OBA structures.
A two-part Action Brief from the National Alliance of Healthcare Purchaser Coalitions (NAHPC) designed specifically for employer/purchaser audiences. Covers CGT basics, workforce impact, coverage considerations, and strategies for equitable, affordable access.
Companion employer action roadmap outlining five action steps: (1) determine population and pipeline risk; (2) explore coverage options; (3) consider non-traditional payment options including outcomes-based agreements (OBAs); (4) become familiar with Centers of Excellence (COEs); and (5) educate employees. Includes data on therapy costs ($300K–$3.5M).
A practitioner-focused action brief from the Midwest Business Group on Health (MBGH) examining ultra-high-cost therapies in the employer market and documenting real employer solutions. Useful for mid-market employers seeking peer benchmarking on CGT coverage strategy.
The Purchaser Business Group on Health (PBGH) represents 40 private employers and public entities spending $350 billion annually. PBGH develops best practices for value-based purchasing, including specialty drug management relevant to CGTs.
The Integrated Benefits Institute (IBI) found that 33% of U.S. employers currently include cell and gene therapies in benefit plans, with 36% actively evaluating inclusion — based on responses from more than 400 employers and 200 benefits consultants.
Comprehensive summary of all 2024 FDA approvals in the CGT space, covering Lenmeldy, Beqvez, Tecelra (the first engineered cell therapy for a solid tumor), Kebilidi (the first gene therapy administered directly to the brain), and Ryoncil. Benefits managers can use this to update formulary and coverage policy documentation.
No resources match your search. Try a different keyword or filter.
Disclaimer: This resource hub is provided for educational and informational purposes only. It does not constitute legal, actuarial, medical, or benefits advice. Employers should consult qualified ERISA counsel, benefits consultants, actuaries, and clinical advisors before making coverage, financing, or plan design decisions. All external links are provided for reference and do not imply endorsement.